News | September 30, 2014

First U.S. Production Facility of Molybdenum-99 Isotope to be Built in Florida

nuclear imaging, isotopes, Molybdenum-99
September 30, 2014 — Coquí RadioPharmaceuticals Corp. is working to become the first commercial producer of lifesaving medical isotopes in the United States. In 2012, Congress passed legislation that was signed by President Obama making it a national priority to produce Molybdenum-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer.
 
“Among the aspiring medical isotope production companies planning to build facilities in the United States, Coquí Pharma is the only one using a design and production method already demonstrated throughout the world as safe, efficient and reliable,” stated Carmen Bigles, CEO of Coquí. Coquí Pharma recently announced their plans to construct the medical isotope production facility at the Sid Martin Biotechnology Incubator in Progress Corporate Park, Alachua, Florida, near Gainesville.
 
Specifically, the facility will be producing Molybdenum-99, the parent isotope of Technetium-99, the isotope used in 80 percent of nuclear medicine procedures. Once operational, Coquí Pharma will be capable of supplying a large portion of the U.S. market and, ultimately, the international market as well. 
 
“These isotopes are critical to the diagnosis and treatment of several diseases, and we believe that now is the time for someone to step up and provide new leadership in this highly important industry,” Bigles remarked.
 
International production sources tend to be older and frequently unreliable, which can delay delivery of potentially life-saving medical diagnostics and treatments to patients. International facilities also tend to use highly enriched uranium, which can raise nuclear proliferation concerns. Coquí has selected INVAP, an internationally-recognized Argentinian firm, to design and construct the proposed facility. INVAP has designed and constructed a number of similar facilities around the world, including the OPAL research reactor in Australia, the RA-3 in Argentina, and other facilities that are successfully producing Mo-99 with low enriched uranium.
 
Read the 2017 article "FDA Clears Path for First Domestic Supply of Tc-99m Isotope." 
 
For more information: www.coquipharma.com

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...